Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 3:43 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 2,810 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: matched control group Clear all
Completed Phase 4 Interventional Results available

Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder.

NCT01093534
View directory record Official record
Conditions
Detrusor Overactivity, Overactive Bladder
Interventions
Placebo, solifenacin
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
547 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
3
States / cities
New York, New York • West Reading, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Nov 1, 2026, 3:43 AM EST
Completed Phase 3 Interventional Results available

Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH)

NCT03156621
View directory record Official record
Conditions
Homozygous Familial Hypercholesterolemia
Interventions
Alirocumab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
4
States / cities
Boca Raton, Florida • New York, New York • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2021 · Synced Nov 1, 2026, 3:43 AM EST
Recruiting Phase 1 Interventional Accepts healthy volunteers

First-in-Human Single and Multiple Dose of HL-400

NCT06997484
View directory record Official record
Conditions
Parkinson Disease
Interventions
HL-400, Placebo
Drug
Lead sponsor
Highlightll Pharmaceutical (USA) LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Nov 1, 2026, 3:43 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Neural Mechanisms of CBT Response in Hoarding Disorder

NCT01956344
View directory record Official record
Conditions
Obsessive Compulsive Disorder
Interventions
Cognitive Behavioral Therapy
Behavioral
Lead sponsor
Hartford Hospital
Other
Eligibility
20 Years to 60 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 7, 2019 · Synced Nov 1, 2026, 3:43 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-39439335 in Healthy Japanese and Caucasian Adult Male Participants

NCT01631487
View directory record Official record
Conditions
Healthy
Interventions
JNJ-39439335 10 mg, JNJ-39439335 25 mg, JNJ-39439335 50 mg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
20 Years to 55 Years · Male only
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2013 · Synced Nov 1, 2026, 3:43 AM EST
Completed No phase listed Observational

Hippocampal Memory Circuits in Delusions

NCT03822910
View directory record Official record
Conditions
Psychosis
Interventions
Pattern Separation Paradigm, Sequential Associative Mismatch Paradigm, Encoding Plasticity Paradigm
Diagnostic Test
Lead sponsor
NYU Langone Health
Other
Eligibility
16 Years to 35 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Nov 1, 2026, 3:43 AM EST
Completed No phase listed Observational

Persistent Pain After Cystectomy for Bladder Cancer

NCT02751346
View directory record Official record
Conditions
Pain, Surgery, Post Operative Pain
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
383 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 4, 2018 · Synced Nov 1, 2026, 3:43 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and PK of AH-008 Following Single Ascending Dose in Healthy Subjects

NCT07697560
View directory record Official record
Conditions
Chemotherapy-induced Peripheral Neuropathy (CIPN)
Interventions
AH-008 for Injection, 150 mg, AH-008 for Injection, Placebo
Drug
Lead sponsor
AnHorn Medicines Co. Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Nov 1, 2026, 3:43 AM EST
Completed Phase 3 Interventional Results available

Relapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder

NCT00887224
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Desvenlafaxine succinate sustained release 50 mg, Desvenlafaxine succinate sustained release 25 mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
874 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
21
States / cities
Beverly Hills, California • Encino, California • Los Alamitos, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2014 · Synced Nov 1, 2026, 3:43 AM EST
Completed Phase 2 Interventional Results available

A Study of Lampalizumab Intravitreal Injections Administered Every Two Weeks or Every Four Weeks to Participants With Geographic Atrophy

NCT02288559
View directory record Official record
Conditions
Geographic Atrophy
Interventions
Sham, Lampalizumab
Other · Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
60 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
36
States / cities
Mesa, Arizona • Tucson, Arizona • Springdale, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Nov 1, 2026, 3:43 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Pharmacokinetics of KPG-818 in Healthy Subjects

NCT03949426
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
KPG-818
Drug
Lead sponsor
Kangpu Biopharmaceuticals, Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Nov 1, 2026, 3:43 AM EST
Completed Phase 3 Interventional Results available

Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine

NCT02605174
View directory record Official record
Conditions
Migraine With or Without Aura
Interventions
Lasmiditan 50 mg, Lasmiditan 100 mg, Lasmiditan 200 mg, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
3,005 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
95
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 80 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2019 · Synced Nov 1, 2026, 3:43 AM EST
Completed Phase 4 Interventional Results available

A Clinical Study in Patients With Overactive Bladder With Leakage of Urine, to Find Out if the Medicine, Fesoterodine, Works in Those Patients Who Did Not Have Enough Response to the Medicine, Tolterodine.

NCT01302054
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
Fesoterodine 8 mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
990 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
109
States / cities
Birmingham, Alabama • Fairhope, Alabama • Chandler, Arizona + 80 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2018 · Synced Nov 1, 2026, 3:43 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Improving the Diagnosis of Common Variable Immune Deficiency

NCT03335605
View directory record Official record
Conditions
CVI - Common Variable Immunodeficiency
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
Not listed
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Nov 1, 2026, 3:43 AM EST
Completed Phase 4 Interventional Results available

Adolescent Fibromyalgia Study

NCT01020474
View directory record Official record
Conditions
Fibromyalgia
Interventions
placebo, pregabalin (Lyrica)
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
12 Years to 17 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
30
States / cities
Los Angeles, California • Santa Ana, California • Delray Beach, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Nov 1, 2026, 3:43 AM EST
Completed Not applicable Interventional

Personalized Integrated Alcohol and Sexual Assault Prevention Among College Students

NCT05281874
View directory record Official record
Conditions
Alcohol Drinking, Sexual Assault
Interventions
Positive Change (+Change), A healthy lifestyles attention control, Positive Change (+Change) Plus Booster
Behavioral
Lead sponsor
Georgia State University
Other
Eligibility
18 Years to 25 Years
Enrollment
1,116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Nov 1, 2026, 3:43 AM EST
Recruiting Phase 3 Interventional

Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

NCT07179380
View directory record Official record
Conditions
Pulmonary Hypertension, Interstitial Lung Disease
Interventions
Treprostinil Palmitil Inhalation Powder, Placebo
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years and older
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
19
States / cities
Phoenix, Arizona • Fresno, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Nov 1, 2026, 3:43 AM EST
Recruiting No phase listed Observational Accepts healthy volunteers

Triple EIT (Electrical Impedance Tomography)

NCT07247474
View directory record Official record
Conditions
Neonates and Preterm Infants, Cardiopulmonary
Interventions
Electrical impedance tomography (EIT)
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
2 Weeks to 25 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Nov 1, 2026, 3:43 AM EST
Recruiting Not applicable Interventional

Testing a Brief Motivational Intervention to Increase Physical Activity for Cancer Survivors

NCT07215091
View directory record Official record
Conditions
Cancer
Interventions
Brief Motivational Intervention
Behavioral
Lead sponsor
Stony Brook University
Other
Eligibility
Not listed
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Nov 1, 2026, 3:43 AM EST
Completed Phase 1 Interventional Results available

Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant

NCT00513474
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
busulfan, cyclophosphamide, cyclosporin-A, etoposide, methotrexate, rasburicase, sirolimus, tacrolimus, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, total-body irradiation, fludarabine, allopurinol
Drug · Procedure · Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 25, 2017 · Synced Nov 1, 2026, 3:43 AM EST
Completed Not applicable Interventional

Exoskeleton-assisted Walking in SCI Inpatient Rehabilitation

NCT04013997
View directory record Official record
Conditions
Spinal Cord Injuries, Inpatients
Interventions
EksoGT
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 10, 2019 · Synced Nov 1, 2026, 3:43 AM EST
Completed No phase listed Observational

Genomic Profiling Assay in Phase I

NCT02437617
View directory record Official record
Conditions
Advanced Cancers
Interventions
Tumor Tissue
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Nov 1, 2026, 3:43 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Chemotherapy-Related Changes in Neurocognitive Function and Symptoms in Colorectal Cancer Patients: A Pilot Study

NCT03683004
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 29, 2023 · Synced Nov 1, 2026, 3:43 AM EST
Active, not recruiting No phase listed Observational Accepts healthy volunteers

ACT NOW Longitudinal Study: Outcomes of Babies With Opioid Exposure Study

NCT04149509
View directory record Official record
Conditions
Neonatal Opioid Withdrawal Syndrome
Interventions
Not listed
Lead sponsor
Advancing Clinical Trials in Neonatal Opioid Withdrawal (ACT NOW) Program
Network
Eligibility
Up to 1 Month
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
6
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Durham, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Nov 1, 2026, 3:43 AM EST